CareDx, Inc
CDNA
Κατάταξη σε μετοχές
#4445
CareDx, Inc. is a global innovator specializing in the discovery, development,... CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
Τιμή μετοχής
$67.25
Τελευταίος συγχρονισμός: 2026-10-19
Κεφαλαιοποίηση
$3.48B
Αλλαγή (1 ημέρα)
5.08%
Αλλαγή (1 έτος)
341.85%
Χώρα
US
Εμπόριο CareDx, Inc (CDNA)
Κατηγορία
Healthcare
Κέρδη για την CareDx, Inc (CDNA)
Κέρδη τον Jun 2026 TTM: $115.19M
Σύμφωνα με τις τελευταίες οικονομικές αναφορές της CareDx, Inc, τα τρέχοντα κέρδη της εταιρείας είναι $115.19M. Το 2023, η εταιρεία παρουσίασε κέρδη $-190.14M, μείωση σε σύγκριση με των κερδών του 2022 που ήταν $-76.23M. Τα κέρδη που εμφανίζονται σε αυτή τη σελίδα είναι πριν από τόκους και φόρους, γνωστά και ως EBIT.
Ιστορικό κερδών για την CareDx, Inc από 2012 έως 2026
Κέρδη στο τέλος κάθε έτους
| Έτος | Κέρδη | Αλλαγή |
|---|---|---|
| 2026 (TTM) | $115.19M | 117.92% |
| 2024 | $52.86M | -127.80% |
| 2023 | $-190.14M | 149.42% |
| 2022 | $-76.23M | 137.58% |
| 2021 | $-32.09M | 62.47% |
| 2020 | $-19.75M | -17.53% |
| 2019 | $-23.95M | -50.33% |
| 2018 | $-48.22M | -15.81% |
| 2017 | $-57.27M | 38.46% |
| 2016 | $-41.36M | 201.76% |
| 2015 | $-13.71M | 1,806.40% |
| 2014 | $-719.00K | -79.70% |
| 2013 | $-3.54M | -29.99% |
| 2012 | $-5.06M | 0.00% |
Κέρδη παρόμοιων εταιρειών ή ανταγωνιστών
| Εταιρεία | Κέρδη | Διαφορά Κερδών | Χώρα |
|---|---|---|---|
| $7.61B | 6,505.49% |
US
|
|
| $4.76B | 4,033.97% |
US
|
|
| $-252.70M | -319.37% |
US
|
|
| - | - |
CN
|
|
| $1.66B | 1,339.34% |
US
|
